This site is intended for Healthcare Professionals only.

UK monitoring ‘subvariant’ of coronavirus Delta strain: Govt

Date:

Share post:

The government on Tuesday (October 19) said it was monitoring a subvariant of the Delta strain of the coronavirus, which has been seen in a growing number of cases.

Prime minister Boris Johnson’s spokesman said the government was keeping a “close eye” on the AY.4.2 variant but said there was no evidence it spreads more easily.

“As you would expect, we are monitoring it closely and won’t hesitate to take action if necessary,” he told reporters.

Overall infection rates in Britain remain stubbornly high, despite high rates of vaccination, and on Monday nearly 50,000 new cases of Covid-19 were recorded.

Some scientists have suggested that measures to mitigate close-contact transmission, such as mask-wearing indoors, could be needed to prevent cases spiralling further.

Coronavirus restrictions were lifted across the country in July after three national lockdowns.

The rise has been attributed to high numbers of infections among schoolchildren, and prompted calls for a more wide-ranging booster jab programme to combat waning immunity.

Downing Street has acknowledged the rising numbers of positive tests, hospital admissions and deaths, but pointed to fluctuations in all three rates in recent months.

Francois Balloux, professor of computational systems biology at University College London, said AY.4.2 has two spike mutations found in other coronavirus variants and was first sequenced in April 2020.

The subvariant was “rare” outside Britain and there had been only three cases detected so far in the United States, he added.

“As AY.4.2 is still at fairly low frequency, a 10 percent increase in its transmissibility could have caused only a small number of additional cases.

“As such it hasn’t been driving the recent increase in case numbers in the UK.”

Bayroux, director of the UCL Genetics Institute, added: “This is not a situation comparable to the emergence of Alpha and Delta that were far more transmissible (50 per cent or more) than any strain in circulation at the time.

“Here we are dealing with a potential small increase in transmissibility that would not have a comparable impact on the pandemic.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...